Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note published on Tuesday, Benzinga reports. They currently have a $11.00 price objective on the stock.

A number of other analysts have also recently weighed in on VOR. Oppenheimer reiterated an outperform rating and issued a $15.00 price target (down from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. Stifel Nicolaus lowered their price target on Vor Biopharma from $15.00 to $12.00 and set a buy rating on the stock in a research report on Thursday, March 21st. HC Wainwright reiterated a buy rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Thursday, March 21st. Finally, JMP Securities reiterated a market outperform rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma presently has an average rating of Buy and an average target price of $13.50.

Vor Biopharma Stock Performance

VOR opened at $1.88 on Tuesday. Vor Biopharma has a 1 year low of $1.62 and a 1 year high of $5.70. The stock’s 50 day simple moving average is $2.04 and its 200-day simple moving average is $2.11.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. As a group, equities analysts expect that Vor Biopharma will post -1.34 earnings per share for the current year.

Institutional Trading of Vor Biopharma

An institutional investor recently bought a new position in Vor Biopharma stock. SG Americas Securities LLC bought a new position in shares of Vor Biopharma Inc. (NYSE:VOR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,258 shares of the company’s stock, valued at approximately $37,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.